# Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

> **NCT07227012** · PHASE1,PHASE2 · RECRUITING · sponsor: **Pfizer** · enrollment: 138 (estimated)

## Conditions studied

- Carcinoma, Hepatocellular
- Hepatocellular Cancer
- Hepatocellular Carcinoma
- Unresectable Hepatocellular Carcinoma
- Liver Neoplasms
- Advanced Hepatocellular Carcinoma
- Metastatic Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** PF-08634404
- **BIOLOGICAL:** Ipilimumab

## Key facts

- **NCT ID:** NCT07227012
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2027-10-18
- **Final completion:** 2028-10-17
- **Target enrollment:** 138 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07227012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07227012, "Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07227012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*